NASDAQ:PALI Palisade Bio Q3 2026 Earnings Date & Estimates $1.48 +0.02 (+1.02%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$1.46 -0.02 (-1.69%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Palisade Bio is estimated to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for November 10, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026Conference Call DateNovember 10, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Palisade Bio in Q3 2026Palisade Bio is expected to post earnings of -$0.06 per share on revenue of $0.47 million. In the same quarter a year earlier Palisade Bio reported -$0.38 per share. Palisade Bio last reported on August 10, 2026, posting -$0.05 per share and beating the -$0.0522 consensus estimate. Palisade Bio has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.06Expected Revenue$0.47 millionPrior-Year EPS-$0.38Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.05 (Beat by +$0.0022)Last Quarter Revenue$0.50 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Palisade Bio Q3 2026 Earnings FAQ When does Palisade Bio report Q3 2026 earnings? Palisade Bio (NASDAQ:PALI) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Palisade Bio's Q3 2026 earnings call? Palisade Bio's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Palisade Bio? Analysts expect Palisade Bio to post earnings of -$0.06 per share for Q3 2026. How much revenue is Palisade Bio expected to report? The consensus revenue estimate for Palisade Bio is $0.47 million for Q3 2026. Palisade Bio Earnings HeadlinesPalisade Bio, Inc. Presents New Clinical, Pharmacokinetic, Pharmacodynamic And Mechanistic Data Strengthening Phase 2 Rationale For PALI-2108 In Ulcerative Colitis And Crohn?s ...October 13 at 7:27 PM | marketscreener.comMPalisade Bio Presents PALI-2108 Data Supporting Phase 2 Trials In Inflammatory Bowel DiseaseOctober 12 at 12:58 PM | rttnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s ...October 12 at 12:58 PM | markets.businessinsider.comPalisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026October 12 at 9:00 AM | globenewswire.comRaymond James initiates coverage of Palisade Bio with outperformOctober 9, 2026 | msn.comSee More Palisade Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email. Email Address About Palisade BioPalisade Bio (NASDAQ:PALI) is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases and complications associated with gastrointestinal surgery. The company’s research is centered on treatments designed to address intestinal inflammation, impaired barrier function and other factors that can delay recovery following surgery. Palisade Bio’s lead product candidate is LB1148, an orally administered, locally acting serine protease inhibitor. The company has evaluated LB1148 for postoperative ileus, a temporary disruption of intestinal movement that can occur after abdominal surgery, as well as for other gastrointestinal conditions and surgery-related complications. Palisade Bio is headquartered in San Diego, California, and has advanced LB1148 through clinical development. The company’s programs remain focused on translating its understanding of gastrointestinal inflammation and intestinal barrier function into potential therapies for patients with limited treatment options.View Palisade Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
